🕒 Last update: loading…

Stock Zentalis Pharmaceuticals, Inc. ZNTL

Zentalis Pharmaceuticals, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2020 → 2021: 61.84%

Price change 2021 → 2022: -76.04%

Price change 2022 → 2023: -24.78%

Price change 2023 → 2024: -80.00%

Price change 2024 → 2025: -55.45%

Price change 2025 → 2026: 93.33%

Price change 2026 (year to date): 90.51%

Financial growth

Revenue CAGR (8 years): -100.00%

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.18

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -1.29

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 60.51% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Zentalis Pharmaceuticals, Inc.–0.18–🔒
Bastide Le Confort Médical S.A.21.65.70+10.3 %–
Transgene S.A.–0.02−20.1 %–
Adocia S.A.–5.97+18.8 %–
OrganiGram Holdings Inc.2.00.03––

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Zentalis Pharmaceuticals, Inc. over the latest fiscal years.

Revenue
67.4 m USD
fiscal year 2024
Net income
-166 m USD
fiscal year 2024
Net margin
-246.0 %
fiscal year 2024
Market cap
167 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
201814,000-21.1 m-150,478.6 %n/a
202467.4 m-166 m-246.0 %+481,507.1 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Zentalis Pharmaceuticals, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-6.35
risk zone (below 1.81)
Piotroski Score
0 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.09 x
net cash
Fiscal year20212022202320242025
Cash and investments340 m437 m483 m371 m246 m
Total Debt45.9 m47.3 m45.8 m42.6 m39.6 m
Net Debt-14.0 m4.3 m17.7 m8.7 m3.6 m
Equity364 m434 m437 m337 m216 m
Total assets472 m553 m562 m430 m289 m
Operating cash flow-154 m-164 m-208 m-171 m-125 m
Investments (capex)6.1 m2.5 m583,000221,0000
Free cash-flow-160 m-166 m-208 m-171 m-125 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.71 x
Price / book value0.56 x
Return on Equity (ROE)-75.8 %
Return on Invested Capital (ROIC)-62.3 %
Net margin0.0 %
Debt / equity0.18 x
Current ratio7.33 x
Free cash-flow yield-124.9 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Zentalis Pharmaceuticals, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Zentalis Pharmaceuticals, Inc.167 mn/a0.0 %
Pliant Therapeutics, Inc. PLRX43.2 mn/a0.0 %
Artiva Biotherapeutics, Inc. ARTV198 mn/a0.0 %
Instil Bio, Inc. TIL41.2 mn/a0.0 %
Immix Biopharma, Inc. IMMX657 mn/a0.0 %
Shattuck Labs, Inc. STTK474 mn/a-4,880.9 %
Sutro Biopharma, Inc. STRO163 mn/a-186.4 %
ALX Oncology Holdings Inc. ALXO144 mn/a0.0 %
MacroGenics, Inc. MGNX141 mn/a-49.9 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Zentalis Pharmaceuticals, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
12 analysts

Breakdown of ratings

strong buy 0buy 9hold 3sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 7 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Zentalis Pharmaceuticals, Inc.

Free float
70.9 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 03/04/2020
ISIN code
US98943L1070
Workforce
166
full-time employees
Chief executive
Julie M. Eastland

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Zentalis Pharmaceuticals, Inc.

What is the Zentalis Pharmaceuticals, Inc. share price?

Latest recorded price: 1.70 USD on 13/11/2026, for a market cap of 167 m USD.

What is the revenue of Zentalis Pharmaceuticals, Inc.?

67.4 m USD for fiscal year 2024, with net income of -166 m USD (net margin -246.0 %).

What do analysts say about Zentalis Pharmaceuticals, Inc.?

Out of 12 analysts: 9 buy or strong buy, 3 hold, 0 sell or strong sell.

Is Zentalis Pharmaceuticals, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US98943L1070).

How many employees does Zentalis Pharmaceuticals, Inc. have?

166 full-time employees according to the latest published profile.

Who runs Zentalis Pharmaceuticals, Inc.?

Julie M. Eastland is the company's chief executive.

07

Similar stocks